Early use of Empagliflozin in patients with cardiogenic shock

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of initiating Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in patients experiencing cardiogenic shock. The study focuses on patients who have been on catecholamines for more than 12 hours but less than 5 days, assessing outcomes such as mortality, rehospitalization rates, left ventricular ejection fraction, and renal function over a three-month period. The trial aims to determine if early intervention with Empagliflozin can improve long-term prognosis in this critical patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients hospitalized in critical cardiac unit care or Intensive care unit for a cardiogenic shock
* "Who must have been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock.
* Patients who are able to take oral tablets

Exclusion Criteria:

* GFR\< 20 ml/min/1.73m2.
* Chronic dialysis.
* Patient on SGLT2 inhibitors prior to admission to ICU or CCU.
* Known allergy to SGLT2 inhibitors or to any of its excipients (in particular, patients with hereditary disorders of galactose intolerance, total lactase deficiency or glucose or galactose malabsorption syndrome)
* Patients on lithium.
* Patient in shock for another cause or moribund (SAPS2\> 90).
* Specific cardiogenic shock context:

  1. cardiac transplant patient or on transplant list.
  2. peripartum, adrenergic, valvular, non ischemic, post embolic heart disease.
  3. related to cardiotropic drug intoxication.
  4. Secondary to a cardiac arrest for which the patient remains comatose prior to inclusion.
* Women of childbearing age without effective contraception.
* Person referred to in Articles 10, 31, 32, 33 and 34 of EU Regulation 536/2014 (Pregnant woman, parturient or breastfeeding mother, Minor (not emancipated), Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice))

Where it's running

• CHR Metz - Thionville
  Ars-Laquenexy, France Recruiting
• CHU de Besançon
  Besançon, France Recruiting
• Hôpitaux Universitaires de Strasbourg
  Strasbourg, France Recruiting
• CHRU de NANCY - réanimation médicale
  Vandœuvre-lès-Nancy, France Recruiting
• Chru Nancy - Usic
  Vandœuvre-lès-Nancy, France Recruiting
• CHU de Dijon Bourgogne
  Dijon, France Not yet recruiting

Study contacts

• Study coordinator: Antoine KIMMOUN, MD PhD
• Email: a.kimmoun@chru-nancy.fr
• Phone: 3 83 15 40 79

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock

  This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07769528

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

• CRP Apheresis for infarct-related cardiogenic shock

  This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07687017

• Compare two ventilator modes in adults with cardiac ICU needs and invasive ventilation

  This pilot tests whether volume-controlled versus pressure-controlled ventilation can be safely used in adults with heart disease and respiratory failure who need invasive ventilation.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07656259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.